trial

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCTId NCT01731119

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 2 · Completed

Enrollment 9 (actual)

Sponsored by University of North Carolina, Chapel Hill

Primary completion 2014-08

Synthesized from structured facts only — each point cited above.

Design & status

Phase

Phase 2

Status

Completed

Enrollment

9 (actual)

Study type

Interventional

Allocation

Model

Single Group

Masking

None

Start

2012-12

Primary completion

2014-08

Eligibility

ALL · 6 Years · 19 Years

Interventions & indications

Drugs

Lurasidone

Indications

Psychotic Disorders Schizophrenia Autistic Disorder Asperger Syndrome Schizophreniform Disorder Asperger Syndrome Schizoaffective Disorder Severe Major Depression With Psychotic Features Child Development Disorders, Pervasive Bipolar II Disorder Severe Mood Disorder With Psychotic Features Bipolar Disorder

Investigators

Linmarie Sikich, MDPrincipal Investigator

Sites

1 total

Chapel Hill, United States

Linked catalysts

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and — primary completion2014-08

Facts & assertions

4 sourced

Enrollment

Phase

PHASE2

Primary Completion Date

2014-08

Status

COMPLETED

relationships

The graph out of here

drug

Lurasidone

drug

lead_sponsor

University of North Carolina, Chapel Hill

company

collaborator

Foundation of Hope, North Carolina

company

indication

Psychotic Disorders

indication

Schizophrenia

indication

Autistic Disorder

indication

investigator

Linmarie Sikich, MD

person